Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation From Its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire11/20 20:02

10-Q：Q3 2024 四半期報告書

SEC11/14 05:37

Pasithea Therapeutics Files to Sell 3.74M Shares of Common Stock for Holders

Seeking Alpha10/08 04:52

Pasithea Therapeutics Priced $5M Private Placement of $1.2M Shares At $4.10/Share to Advance Next-Gen Cancer Treatments

Benzinga09/27 15:03

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire09/27 06:44

Sector Update: Health Care

MT Newswires09/27 03:24